PM1183 plus doxorubicin shows interesting activity in small cell lung cancer
2 Pogledi
• 07/14/23
0
0
Ugraditi
administrator
Pretplatnici
Visit http://www.ecancer.org for more
Dr Calvo (START Madrid, Madrid, Spain) talks to ecancertv at ASCO 2015 about data from a Phase 1b study of the transcriptional inhibitor PM1183 in combination with doxorubicin in second line therapy in patients with small cell lung cancer (SCLC)
Prikaži više
Komentari na Facebooku
SORT BY-
Najbolji komentari
-
Najnoviji komentari